



Sarcoma and surger-I-nnsbruck neuroendocrine tumours



acoasso
Österreichische Gesellschaft für Chirurgische Onkologie
Austrian Society of Surgical Oncology



Thursday, 13th and Friday, 14th December 2018

Congress Innsbruck, 6020 Innsbruck, Rennweg 3

PROGRAMME

Congress Presidents:

Stefan Stättner, MD

Manuel Maglione, MD

Florian Primavesi, MD

Medical University of Innsbruck, Dept. of Visceral, Transplant and Thoracic Surgery

Anichstraße 35, A-6020 Innsbruck

Organisation:

MMag. (FH) Linda Partl,

linda.partl@tirol-kliniken.at

www.hpb-innsbruck.at



Welcome

Dear colleagues and friends,

It is our great pleasure to announce our 3rd international and educational multidisciplinary meeting in Innsbruck!

Following the conferences on the multidisciplinary treatment of the pancreas and liver malignancies, we have put together a comprehensive program on the management of neuroendocrine tumour disease and sarcomas.

Staying on track with last years' positive experiences, we will provide a mix of international, national and local experts who will present and discuss the up-to-date management of this complex and rare disorders. Topics will cover all aspects of the disease including tumour biology and novel treatments - as usual with a hepatopancreatic focus.

Keynote lectures from renowned international experts will highlight and round up. Besides the very educational program for junior surgeons and trainees, all participants have the opportunity to get in touch with the speakers very closely and set up a network far across the borders.

We are looking forward to seeing you here in Innsbruck in December.

Linda Partl
Florian Primavesi
Manuel Maglione
Stefan Stättner





Accreditation

The meeting is accredited by
the **Ärzttekammer** (Austrian Medical Association) to provide **17 DFP-Points**.



The **Surger-I-nnsbruck, Sarcoma and Neuroendocrine Tumours**, Innsbruck, Austria, 13/12/2018-14/12/2018 **LEE18-01604** has been accredited by the European Accreditation Council for Continuing Medical Education (**EACCME®**) with **12 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Contact

- **Organizer**

Univ.-Prof. Dr. Dietmar Öfner-Velano, MAS, MSc, F.A.C.S.
Head of Department
Medical University of Innsbruck
Department of Visceral, Transplantation and Thoracic Surgery
Anichstrasse 35
A-6020 Innsbruck

- **Congress Presidents**

Stefan Stättner, MD
Clinical Lead
email: stefan.staettner@tirol-kliniken.at

Manuel Maglione, MD
email: manuel.maglione@tirol-kliniken.at

Florian Primavesi, MD
email: florian.primavesi@tirol-kliniken.at

all:
HPB Team
Medical University of Innsbruck
Department of Visceral, Transplant and Thoracic Surgery
Anichstrasse 35
A-6020 Innsbruck
web: www.chirurgie-innsbruck.at

- **Organisation**

MMag. (FH) Linda Partl
Medical University of Innsbruck
Department of Visceral, Transplantation and Thoracic Surgery
Anichstr. 35
6020 Innsbruck
t: +43 650 2002103
f: +43 50 504 22602
linda.partl@tirol-kliniken.at

- **Conference venue**

Congress Innsbruck
Hall Brussels
Rennweg 3
6020 Innsbruck, Austria
t: +43 (0) 512 5936-1164
f: +43-512-575607
e: m.walter@cmi.at
web: www.cmi.at

Thursday, 13th of December 2018 – GEPNET Day

08:00 – 08:45 Registration

08.50 Welcome

Manuel Maglione, Florian Primavesi, Stefan Stättner, D. Öfner-Velano (Director) - all Innsbruck, Austria


09:00 – 10:30 Introduction

Moderation: M. Massimo Falconi, Milan, Italy; Günther Krejs, Graz, Austria

The landscape of NET in Austria (Florian Primavesi, Innsbruck, Austria)

Epidemiology – true data or just better diagnostics? (Rainer Lipp, Graz, Austria)

Nomenclature and classification of NET – do we all speak the same language? (Patrizia Kump, Graz, Austria) 

Functionality, syndromes and genetics (Susanne Kaser, Innsbruck, Austria) 

Keynote lecture – Pathology – what's new, what's hot? (Aurel Perren, Bern, Switzerland) 

+ Discussion

Product Presentation Baxter Healthcare **Baxter** - Coffee Break 10:30 – 11:00

11:00 – 12:10 II Assessment and biology GEPNET

Moderation: Aurel Perren, Bern, Switzerland; Patrizia Kump, Graz, Austria

Tumour heterogeneity – a look inside (Daniel Neureiter, Salzburg, Austria)

Predictive and personalized medicine – where are we today? (Jorge Barriuso, Manchester, UK)

Future developments – NETomics? (Lukas Niederreiter, Innsbruck, Austria)

Nuclear diagnostic imaging – lighting the darkness (Christian Uprimny, Innsbruck, Austria) 

+ Discussion

Lunch 12:10 – 13:10

13:10 – 14:40 III Treatment GEPNET/liver dominant disease

Moderation: Michael Silva, Oxford, UK; Markus Raderer, Vienna, Austria

Keynote lecture – Cure, palliation or chronic disease (Marianne Pavel, Erlangen, Germany) 

Interventional strategies with curative intent (Reto Bale, Innsbruck, Austria)

Interventional strategies with palliative intent (Johannes Petersen, Innsbruck, Austria)

Treating the target – PRRT (Irene Virgolini, Innsbruck, Austria)

+ Discussion

Coffee Break 14:40 – 15:10

15:10 – 17:00 IV Treatment Part 2

Moderation: Stephen Fenwick, Liverpool, UK; Marianne Pavel, Erlangen, Germany

Systemic treatment – the role of chemotherapy (Angela Djanani, Innsbruck, Austria)

The role of SSA Analogues/QoL (Barbara Kiesewetter, Vienna, Austria) 

Perioperative care (Philipp Riss, Vienna, Austria) 

Future perspectives, trials (Stefano Partelli, Milan, Italy)

+ Discussion

Keynote lecture – Outcomes of surgery in pNET (Massimo Falconi, Milan, Italy) 

Welcome Drink after the Session

Get together Dinner 19:30 at Hotel Innsbruck

Friday, 14th of December 2018

08:30 – 10:00 V Surgery GEPNET

Moderation: Marianne Pavel, Erlangen, Germany; Stefano Partelli, Milan, Italy

Outcomes of Liver resection / debulking (Stephen Fenwick, Liverpool, UK)

Liver transplantation for GEPNET – indications and outcomes (Annemarie Weissenbacher, Innsbruck, Austria)

Is there a role for neoadjuvant/adjuvant treatments? (Markus Raderer, Vienna, Austria)

Moderation: Florian Primavesi, Innsbruck, Austria

Cases and interactive discussion



 **astellas**
This session is sponsored by Astellas Pharma Austria.

Coffee Break 10:00 – 10:30

Sarcoma

10:30 – 12:00 Introduction

Moderation: Alessandro Gronchi, Milan, Italy; Arpad Szatankay, Innsbruck, Austria

The landscape of sarcomas in Austria (Manuel Maglione, Innsbruck, Austria)

Keynote lecture – Definition, Graduation, classification (Alessandro Franchi, Pisa, Italy)



Epidemiology – a truly rare disease? (Alexander Perathoner, Innsbruck, Austria)

Pathology – outline for clinicians (Georg Oberhuber, Innsbruck, Austria)

Molecular Understanding (Arno Amann, Innsbruck, Austria)

Do we always need a biopsy? (Arno Amann, Innsbruck, Austria)

+ Discussion

Lunch 12:00 – 13:00

13:00 – 14:10 II Assessment

Moderation: Stefan Stättner, Innsbruck, Austria; Thomas Brodowicz, Vienna, Austria

Radiology – algorithms (Eva-Maria Gassner, Innsbruck, Austria)



Nuclear and functional imaging (Christian Uprimny, Innsbruck, Austria)

(Functional) assessment before surgery – what do we need? (Reinhold Kafka-Ritsch, Innsbruck, Austria)



High volume for a rare disease – centralisation (Hassan Malik, Liverpool, UK)

+ Discussion

Coffee Break 14:10 – 14:40

14:40 – 17:00 III Treatment

Moderation: Alessandro Franchi, Pisa, Italy; Hassan Malik, Liverpool, UK

The role of radiotherapy – pre, intra or postop? (Arpad Szatankay, Innsbruck, Austria)

The role of systemic therapy (Thomas Brodowicz, Vienna, Austria)

Liver surgery – indications and outcomes (Michael Silva, Oxford, UK)

Keynote lecture – What is the right surgery for abdominal/retroperitoneal sarcoma? (Alessandro Gronchi, Milan, Italy)



+ Discussion

Moderation: Manuel Maglione, Innsbruck, Austria

Cases and interactive Board



17:00

Closing remarks

Invited Faculty

- Barriuso Jorge, The University of Manchester, Faculty of Biology, Medicine and Health, Manchester, UK
 - Brodowicz Thomas, Medical University of Vienna, Clinical Division of Oncology, Austria
 - Falconi Massimo, UniSR San Raffaele, Milan, Italy
 - Fenwick Stephen, Aintree University Hospital, Liverpool, UK
 - Franchi Alessandro, Università di Pisa, Anatomia Patologica, Pisa, Italy
 - Gronchi Alessandro, National Cancer Institute, Department of Surgery, Milan, Italy
 - Kieseewetter Barbara, Medical University of Vienna, Clinical Division of Oncology, Austria
 - Krejs Günther, Medical University of Graz, Clinical Department of Gastroenterology and Hepatology, Austria
 - Kump Patrizia, Medical University of Graz, Clinical Department of Gastroenterology and Hepatology, Austria
 - Lipp Rainer, Medical University of Graz, Clinical Division of Oncology, Austria
 - Malik Hassan, Aintree University Hospital, Liverpool, UK
 - Neureiter Daniel, Paracelsus Medical University, Pathology Institute, Salzburg, Austria
 - Partelli Stefano, UniSR San Raffaele, Milan, Italy
 - Pavel Marianne, University Hospital Erlangen, CCC, Germany
 - Perren Aurel, University of Bern, Institute of Pathology, Switzerland
 - Raderer Markus, Medical University of Vienna, Clinical Division of Oncology, Austria
 - Riss Philipp, Medical University of Vienna, Clinical Department of General Surgery, Austria
 - Silva Michael, Oxford University Hospitals NHS Trust, Department of General Surgery and Trauma, Oxford, UK
- Amann Arno, Bale Reto, Djanani Angela, Gassner Eva-Maria, Kafka-Ritsch Reinhold, Kaser Susanne, Maglione Manuel, Niederreiter Lukas, Oberhuber Georg, Öfner-Velano Dietmar, Perathoner Alexander, Petersen Johannes, Primavesi Florian, Stättner Stefan, Sztankay Arpad, Uprimny Christian, Virgolini Irene, Weissenbacher Annemarie
Medical University Innsbruck, Austria



ENSEAL™

Better Sealing.¹⁻⁵

The ENSEAL™ X1 Large Jaw

Can enable **better sealing** compared to other technologies¹⁻⁴



Better Hemostasis¹

88% less bleeding in thick tissue possible¹



Better Tissue Management⁶

41% less thermal spread and smaller thermal footprint with Adaptive Tissue Technology possible⁶



Better Design⁷

Highly intuitive steps-for-use, convenient controls and 360° rotation⁷

References: **1** ENSEAL® X1 Large Jaw had significantly less bleeding at the distal tip vs LigaSure Impact™. Preclinical test of distal tip bleeding (ENSEAL® vs. Impact-LF-4318) in thick porcine mesentery base (p<0.001). May 2018. Data on file (C2617). **2** ENSEAL® X1 Large Jaw had significantly less lateral thermal spread than LigaSure® Impact. Preclinical testing on porcine carotids (ENSEAL® vs. Impact-LF-4318) that measured mean max lateral thermal damage via histology showed ENSEAL at 41% less thermal spread than LigaSure (p=0.005) Ethicon, PSB004570, Final Report Brick Thermal Damage vs Impact, November 2016, Data on file (C2155). **3** ENSEAL® X1 Large Jaw Tissue Sealer has a better design - with convenient controls and 360° rotation - compared to LigaSure Impact™. Ethicon, DOC022221, Memo X1 Large Jaw better design and ergonomics vs Impact, January 2016, Data on file (C2114). **4** ENSEAL® X1 Large Jaw has a larger distal electrode surface area than LigaSure® Impact. Ethicon, DOC022209A Brick Superior Distal Tip Sealing Rationale, August 2016, Data on file (C2166). **5** The 360° shaft rotation of the ENSEAL® X1 Large Jaw was designed to improve access to hard to reach anatomy/areas. Ethicon, DOC022221, Memo X1 Large Jaw better design and ergonomics vs Impact, January 2016, Data on file (C2158). **6** ENSEAL® X1 Large Jaw had significantly less lateral thermal spread than LigaSure® Impact. Preclinical testing on porcine carotids (ENSEAL® vs. Impact-LF-4318) that measured mean max lateral thermal damage via histology showed ENSEAL at 41% less thermal spread than LigaSure (p=0.005) Ethicon, PSB004570, Final Report Brick Thermal Damage vs Impact, November 2016, Data on file (C2155). **7** ENSEAL® X1 Large Jaw Tissue Sealer has a better design - with convenient controls and 360° rotation - compared to LigaSure Impact™. Ethicon, DOC022221, Miller Memo X1 Large Jaw, January 2016, Data on file (C2114).

Please always refer to the Instructions for Use / Package Insert that come with the device for the most current and complete instructions.

The third-party trademarks used herein are the property of their respective owners.

Johnson & Johnson Medical Products GmbH
Vogartenstraße 206B
1020 Wien

www.jnjmedical.at

ETHICON
PART OF THE **Johnson & Johnson** FAMILY OF COMPANIES

Shaping
the future
of surgery


© Ethicon Endo-Surgery (Europe) GmbH 2018, 073412/180525 EMEA

medwhizz®

my congress companion

Surger-I-nnsbruck 2018

Be whizzy! Go digital!



1

Download

Go to the App Store or to Google Play, enter **medwhizz** and install.

2

Inform

Congresses
Program
Abstracts

3

Take part in

Live-Votings



Download now:



Download on the
App Store



GET IT ON
Google Play

Sponsors

Baxter



ETHICON
PART OF THE Johnson & Johnson FAMILY OF COMPANIES



FoBiCH/ÖGC

Lilly

B Braun

Neovii

Novartis

THP

AMI

BK Medical

Astellas

Chiesi